Drug Approval | May 30, 2024
Alembic Pharmaceuticals receives USFDA final approval for Sacubitril and Valsartan Tablets
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
_256_384.jpg)
Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection
For use with Hamamatsu Images acquired with the NanoZoomer S360MD slide scanner
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
Additional data from APPRAISE ATP trial reinforce modular therapy approach
The award recognizes powerful science–industry collaborations for social good
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Subscribe To Our Newsletter & Stay Updated
